The American public health agency – the Center for Disease Prevention and Control (CDC) – on Friday recommended a vaccine developed by Pfizer against respiratory syncytial virus (RSV), which can be administered to pregnant women with the aim of protecting their babies against severe forms of the disease caused by this virus, informs DPA according to Agerpres.
RSV is the leading cause of hospitalization for infants in the United States. The new vaccine produced by Pfizer, the bivalent RSVpreF serum, marketed under the name Abrysvo, has been shown to reduce the risk of hospitalization of babies by 57% in the first six months after their birth, CDC representatives said in a statement.
To maximize protection for babies after birth, the CDC recommends a seasonal dose of RSV vaccine for pregnant women between 32 and 36 weeks pregnant.
It is the first time that eligible people will be able to receive Pfizer vaccines to help protect against RSV, COVID-19 and pneumococcal pneumonia, representatives of the American pharmaceutical company said.
On Friday, the members of the Advisory Committee on Immunization Practices (ACIP) decided with 11 votes “for” and one “against” the recommendation of the maternal RSV vaccine for pregnant women between the 32nd and 36th weeks of pregnancy, using the seasonal administration, to prevent lower respiratory tract infection with RSV among infants.
Also, the same committee voted to approve the inclusion of the bivalent RSVpreF vaccine produced by Pfizer in the Children’s Vaccination Program, which addresses pregnant women under the age of 19.
2023-09-23 08:04:51
#Centers #Disease #Control #Prevention #recommends #vaccine #developed #Pfizer #respiratory #syncytial #virus
